Alejandro Chen Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alejandro Chen Liang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Yeison Cruz Castillo
Universidad Autónoma de Santo Domingo, Santo Domingo, Dominican Republic
7 shared publications - Ernesto Calderon Martinez
Department of Internal Medicine, Texas Tech University Health Science Center At El Paso , 2000 Transmountain, El Paso, TX 79912
6 shared publications - Lorena María Murrieta Bruciaga
Universidad del Valle de México, Hermosillo, Sonora, México
4 shared publications - Salma Alejandra Beltran Covarrubias
Faculty of Medicine, Universidad de Guadalajara , Guadalajara
3 shared publications - Hector Jonan Flores Uribe
Centro de Estudios Universitarios Xochicalco Campus Tijuana Tijuana México
2 shared publications - Jariel Abreu Perez
Universidad Católica Nordestana, San Francisco de Macorís, Dominican Republic
2 shared publications
Latest Publications
- 13 November 2026
- Published by Elsevier in Journal of Critical Care
- Vol. 97, 155804
Prognostic value of the lactate-to-albumin ratio for mortality in patients with sepsis: A systematic review and meta-analysis
- 13 November 2026
- Published by Elsevier in Journal of Critical Care
- Vol. 97, 155804
Prognostic value of the lactate-to-albumin ratio for mortality in patients with sepsis: A systematic review and meta-analysis
- 30 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in randomized trials. Methods: We systematically searched PubMed/MEDLINE, Web of Science, CINAHL, and Scopus through September 2026 following PRISMA guidelines (PROSPERO: CRD420251231232). RCTs comparing ENZ plus another pharmacologic agent with ENZ monotherapy in mCRPC were included. Analyzed outcomes included overall survival (OS), progression-free survival (PFS), radiographic PFS (rPFS), PSA progression, and adverse events. Random-effects meta-analyses used restricted maximum likelihood estimation with Hartung–Knapp adjustment. Certainty of evidence was assessed using GRADE. Results: Nine trials involving 3779 patients were included. Adding specific agents to ENZ improved rPFS (HR = 0.76; 95% CI, 0.62–0.94; p = 0.02) but did not significantly improve OS, PFS, or PSA progression. Combination therapy increased the risk of any adverse event (RR = 1.03; 95% CI, 1.01–1.06) and grade ≥3 adverse events (RR = 1.37; 95% CI, 1.09–1.71). Estimates for individual adverse events were inconsistent and imprecise. Conclusion: Adding specific agents to ENZ improved pooled rPFS but increased toxicity, without clear evidence of an OS benefit in unselected mCRPC populations (certainty of evidence ranging from very low to moderate across outcomes). These findings should be interpreted cautiously and do not exclude potential benefits from particular combinations in biomarker-selected populations.
- 30 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in randomized trials. Methods: We systematically searched PubMed/MEDLINE, Web of Science, CINAHL, and Scopus through September 2026 following PRISMA guidelines (PROSPERO: CRD420251231232). RCTs comparing ENZ plus another pharmacologic agent with ENZ monotherapy in mCRPC were included. Analyzed outcomes included overall survival (OS), progression-free survival (PFS), radiographic PFS (rPFS), PSA progression, and adverse events. Random-effects meta-analyses used restricted maximum likelihood estimation with Hartung–Knapp adjustment. Certainty of evidence was assessed using GRADE. Results: Nine trials involving 3779 patients were included. Adding specific agents to ENZ improved rPFS (HR = 0.76; 95% CI, 0.62–0.94; p = 0.02) but did not significantly improve OS, PFS, or PSA progression. Combination therapy increased the risk of any adverse event (RR = 1.03; 95% CI, 1.01–1.06) and grade ≥3 adverse events (RR = 1.37; 95% CI, 1.09–1.71). Estimates for individual adverse events were inconsistent and imprecise. Conclusion: Adding specific agents to ENZ improved pooled rPFS but increased toxicity, without clear evidence of an OS benefit in unselected mCRPC populations (certainty of evidence ranging from very low to moderate across outcomes). These findings should be interpreted cautiously and do not exclude potential benefits from particular combinations in biomarker-selected populations.
- 16 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 4932-4957
Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis
Hypertriglyceridemia-induced acute pancreatitis is associated with high triglyceride levels and may lead to significant clinical complications. Rapid TG-lowering strategies, including insulin, therapeutic plasma exchange (TPE), heparin, hemofiltration, and conservative management, are used in clinical practice; however, their comparative efficacy and impact on clinical outcomes remain uncertain. Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and International Prospective Register of Systematic Reviews (PROSPERO) registration (CRD420251239674), we searched PubMed, Embase, Web of Science, Scopus, CINAHL, Google Scholar, and Cochrane. Primary outcomes included TG reduction, C-reactive protein (CRP), length of stay, mortality, and organ failure. Secondary outcomes included renal and respiratory failure. Random-effects network meta-analyses estimated mean differences or relative risks with 95% confidence intervals; treatments were ranked using the Surface Under the Cumulative Ranking curve (SUCRA). Predefined sensitivity analyses were conducted according to study design (RCTs) and risk of bias (ROB). Across predominantly observational evidence, no intervention demonstrated statistically significant superiority over insulin-based therapy for mortality, organ failure, or length of stay, and no consistent clinical benefit was observed despite differences in biochemical TG reduction. Although some interventions showed relatively favorable SUCRA rankings across selected outcomes, these findings were not consistently supported by statistically significant or high-certainty evidence. In RCT-restricted analyses, therapeutic plasma exchange (TPE) significantly reduced TG levels versus insulin (MD - 620.0; p = 0.03) and CRP versus conservative therapy (MD - 0.80; p < 0.01), while insulin plus heparin was associated with shorter hospital stay (MD - 1.60 days; p < 0.01). However, faster triglyceride reduction did not consistently translate into improved mortality, organ failure, ICU-related outcomes, or length of stay. Despite improvements in biochemical markers, the clinical significance of rapid TG reduction in HTG-AP remains uncertain, as these effects were not consistently associated with improvements in mortality, organ failure, ICU-related outcomes, or hospital length of stay. Given that most available evidence was derived from nonrandomized studies and that the certainty of evidence was predominantly low or very low, adequately powered randomized controlled trials are needed to determine whether accelerated triglyceride lowering improves clinically meaningful patient outcomes.
- 16 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 4932-4957
Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis
Hypertriglyceridemia-induced acute pancreatitis is associated with high triglyceride levels and may lead to significant clinical complications. Rapid TG-lowering strategies, including insulin, therapeutic plasma exchange (TPE), heparin, hemofiltration, and conservative management, are used in clinical practice; however, their comparative efficacy and impact on clinical outcomes remain uncertain. Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and International Prospective Register of Systematic Reviews (PROSPERO) registration (CRD420251239674), we searched PubMed, Embase, Web of Science, Scopus, CINAHL, Google Scholar, and Cochrane. Primary outcomes included TG reduction, C-reactive protein (CRP), length of stay, mortality, and organ failure. Secondary outcomes included renal and respiratory failure. Random-effects network meta-analyses estimated mean differences or relative risks with 95% confidence intervals; treatments were ranked using the Surface Under the Cumulative Ranking curve (SUCRA). Predefined sensitivity analyses were conducted according to study design (RCTs) and risk of bias (ROB). Across predominantly observational evidence, no intervention demonstrated statistically significant superiority over insulin-based therapy for mortality, organ failure, or length of stay, and no consistent clinical benefit was observed despite differences in biochemical TG reduction. Although some interventions showed relatively favorable SUCRA rankings across selected outcomes, these findings were not consistently supported by statistically significant or high-certainty evidence. In RCT-restricted analyses, therapeutic plasma exchange (TPE) significantly reduced TG levels versus insulin (MD - 620.0; p = 0.03) and CRP versus conservative therapy (MD - 0.80; p < 0.01), while insulin plus heparin was associated with shorter hospital stay (MD - 1.60 days; p < 0.01). However, faster triglyceride reduction did not consistently translate into improved mortality, organ failure, ICU-related outcomes, or length of stay. Despite improvements in biochemical markers, the clinical significance of rapid TG reduction in HTG-AP remains uncertain, as these effects were not consistently associated with improvements in mortality, organ failure, ICU-related outcomes, or hospital length of stay. Given that most available evidence was derived from nonrandomized studies and that the certainty of evidence was predominantly low or very low, adequately powered randomized controlled trials are needed to determine whether accelerated triglyceride lowering improves clinically meaningful patient outcomes.
- Open Access
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6) , sfag070
Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis
Background: Anemia is a common complication in chronic kidney disease (CKD), especially in hemodialysis patients, causing fatigue and reduced quality of life. Standard treatments involve iron and erythropoietin (EPO). Ascorbic acid (vitamin C) supports iron metabolism by converting ferric to ferrous iron and enhancing absorption and mobilization. This systematic review and meta-analysis evaluated the effectiveness of ascorbic acid in improving hematologic and iron parameters in adult anemic patients undergoing maintenance hemodialysis. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was performed in PubMed, EMBASE, Cochrane, Scopus, Web of Science, CINAHL and Google Scholar through May 2025. Only randomized controlled trials and crossover studies assessing ascorbic acid in adult anemic hemodialysis patients were included. The protocol was registered in the International Prospective Register of Systematic Review (PROSPERO) (CRD420251056337). Primary outcomes were hemoglobin (Hb), ferritin, serum iron, transferrin saturation (TSAT) and total iron-binding capacity (TIBC). Meta-analyses used DerSimonian-Laird random-effects models. Results: Of 479 screened articles, 14 studies were included. Ascorbic acid supplementation was associated with a modest but significant increase in Hb [mean difference (MD) 0.94 g/dL; 95% confidence interval (CI) 0.57 to 1.31; P < .01; I² = 87.2%] and TSAT (MD 6.86%; 95% CI 1.93 to 11.78; P < .01; I² = 96.7%). Ferritin levels showed a slight but significant reduction (MD −65.00 ng/mL; 95% CI −117.20 to −12.80; P = .01; I² = 57.2%), along with a decrease in TIBC (MD −22.54 µg/dL; 95% CI −42.37 to −2.72; P = .03; I² = 76.1%). EPO requirements expressed as units/kg/week were significantly reduced (MD −21.29; 95% CI −27.73 to −14.84; P < .01; I² = 0.0%). No significant changes were observed in serum iron levels or EPO dosage expressed as IU/week. Conclusion: Ascorbic acid supplementation may confer modest hematologic benefits in hemodialysis patients with improvements in Hb, TSAT and iron utilization, and a small reduction in weight-adjusted erythropoiesis-stimulating agent dose. However, the certainty of evidence is low, and long-term safety and patient-centered outcomes remain unestablished.
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6) , sfag070
Open AccessAscorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis
Background: Anemia is a common complication in chronic kidney disease (CKD), especially in hemodialysis patients, causing fatigue and reduced quality of life. Standard treatments involve iron and erythropoietin (EPO). Ascorbic acid (vitamin C) supports iron metabolism by converting ferric to ferrous iron and enhancing absorption and mobilization. This systematic review and meta-analysis evaluated the effectiveness of ascorbic acid in improving hematologic and iron parameters in adult anemic patients undergoing maintenance hemodialysis. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was performed in PubMed, EMBASE, Cochrane, Scopus, Web of Science, CINAHL and Google Scholar through May 2025. Only randomized controlled trials and crossover studies assessing ascorbic acid in adult anemic hemodialysis patients were included. The protocol was registered in the International Prospective Register of Systematic Review (PROSPERO) (CRD420251056337). Primary outcomes were hemoglobin (Hb), ferritin, serum iron, transferrin saturation (TSAT) and total iron-binding capacity (TIBC). Meta-analyses used DerSimonian-Laird random-effects models. Results: Of 479 screened articles, 14 studies were included. Ascorbic acid supplementation was associated with a modest but significant increase in Hb [mean difference (MD) 0.94 g/dL; 95% confidence interval (CI) 0.57 to 1.31; P < .01; I² = 87.2%] and TSAT (MD 6.86%; 95% CI 1.93 to 11.78; P < .01; I² = 96.7%). Ferritin levels showed a slight but significant reduction (MD −65.00 ng/mL; 95% CI −117.20 to −12.80; P = .01; I² = 57.2%), along with a decrease in TIBC (MD −22.54 µg/dL; 95% CI −42.37 to −2.72; P = .03; I² = 76.1%). EPO requirements expressed as units/kg/week were significantly reduced (MD −21.29; 95% CI −27.73 to −14.84; P < .01; I² = 0.0%). No significant changes were observed in serum iron levels or EPO dosage expressed as IU/week. Conclusion: Ascorbic acid supplementation may confer modest hematologic benefits in hemodialysis patients with improvements in Hb, TSAT and iron utilization, and a small reduction in weight-adjusted erythropoiesis-stimulating agent dose. However, the certainty of evidence is low, and long-term safety and patient-centered outcomes remain unestablished.
- 30 March 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 136
Oral isotretinoin combined with antihistaminics for the treatment of acne vulgaris: a systematic review, meta-analysis and trial sequential analysis with GRADE assessment of randomized controlled trials
- 30 March 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 136
Oral isotretinoin combined with antihistaminics for the treatment of acne vulgaris: a systematic review, meta-analysis and trial sequential analysis with GRADE assessment of randomized controlled trials
- Open Access
- 25 March 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (5) , 3596-3608
Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis
Background Gastric variceal bleeding is a life-threatening complication of portal hypertension. Cyanoacrylate injection is the standard endoscopic treatment that carries a significant risk of ectopic embolization, particularly in patients with gastrorenal shunts. Adding endoscopic clips before injection may enhance safety and efficacy, yet evidence remains limited. This study evaluates the safety and effectiveness of clip-assisted cyanoacrylate injection (clip-ECI). Methodology A systematic search was conducted on PubMed, Web of Science, CINAHL, Embase, Google Scholar, and the Cochrane Library on October 9, 2025, following the PRISMA 2020 guidelines. The protocol was registered on PROSPERO (CRD420251166002). The primary outcome was rebleeding. Secondary outcomes included technical success, adverse events, ectopic embolism, and procedure-related mortality. Meta-analysis was performed using R version 3.4.3 (R Core Team) with a random-effects model expressed as proportions and 95% confidence intervals (CIs). Results Six studies involving 465 participants treated with clip-ECI were included, four in the meta-analysis due to overlapping populations. Most participants were middle-aged males with cirrhosis from hepatitis B, presenting with GOV2 or IGV1 gastric varices; 41.7–100% had gastrorenal shunts. The pooled technical success rate was 99% (95% CI 0.97–1.0; p = 0.97; I2 = 0%), rebleeding 11% (95% CI 0.08–0.16; p = 0.1; I2 = 50.4%), adverse events 20% (95% CI 0.15–0.26; p = 0.37; I2 = 0%), ectopic embolism 3% (95% CI 0.00–0.37; p = 0.01; I2 = 85.1%), deaths attributable to ectopic embolism 1% (95% CI 0.00–0.04; p = 0.67; I2 = 0%) and overall mortality 4% (95% CI 0.01–0.14; p = 0.01; I2 = 80.6%). Compared with conventional injection, clip-ECI showed fewer embolic complications and a non-significant trend toward lower rebleeding. Conclusion Clip-ECI appears highly effective with low rebleeding and embolic complication rates, supporting its safety for gastric varices, particularly in patients with gastrorenal shunts. Large multicenter randomized trials are needed to strengthen these findings and establish clinical protocols.
- 25 March 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (5) , 3596-3608
Open AccessEfficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis
Background Gastric variceal bleeding is a life-threatening complication of portal hypertension. Cyanoacrylate injection is the standard endoscopic treatment that carries a significant risk of ectopic embolization, particularly in patients with gastrorenal shunts. Adding endoscopic clips before injection may enhance safety and efficacy, yet evidence remains limited. This study evaluates the safety and effectiveness of clip-assisted cyanoacrylate injection (clip-ECI). Methodology A systematic search was conducted on PubMed, Web of Science, CINAHL, Embase, Google Scholar, and the Cochrane Library on October 9, 2025, following the PRISMA 2020 guidelines. The protocol was registered on PROSPERO (CRD420251166002). The primary outcome was rebleeding. Secondary outcomes included technical success, adverse events, ectopic embolism, and procedure-related mortality. Meta-analysis was performed using R version 3.4.3 (R Core Team) with a random-effects model expressed as proportions and 95% confidence intervals (CIs). Results Six studies involving 465 participants treated with clip-ECI were included, four in the meta-analysis due to overlapping populations. Most participants were middle-aged males with cirrhosis from hepatitis B, presenting with GOV2 or IGV1 gastric varices; 41.7–100% had gastrorenal shunts. The pooled technical success rate was 99% (95% CI 0.97–1.0; p = 0.97; I2 = 0%), rebleeding 11% (95% CI 0.08–0.16; p = 0.1; I2 = 50.4%), adverse events 20% (95% CI 0.15–0.26; p = 0.37; I2 = 0%), ectopic embolism 3% (95% CI 0.00–0.37; p = 0.01; I2 = 85.1%), deaths attributable to ectopic embolism 1% (95% CI 0.00–0.04; p = 0.67; I2 = 0%) and overall mortality 4% (95% CI 0.01–0.14; p = 0.01; I2 = 80.6%). Compared with conventional injection, clip-ECI showed fewer embolic complications and a non-significant trend toward lower rebleeding. Conclusion Clip-ECI appears highly effective with low rebleeding and embolic complication rates, supporting its safety for gastric varices, particularly in patients with gastrorenal shunts. Large multicenter randomized trials are needed to strengthen these findings and establish clinical protocols.